News | February 17, 2010

New Source of Vital Medical Isotopes Announced

February 17, 2010 — An agreement has been reached to further augment and diversify a manufacturer's supply of molybdenum 99 (Mo 99) to produce the medical isotope technetium 99m (Tc 99m).

Tc 99m is a vital medical isotope used in more than 80 percent of all nuclear medicine diagnostic and functional studies of organs and anatomical systems. The information from these studies is used by many medical specialists (including radiologists, nephrologists, oncologists and cardiologists) to better diagnose and treat patients. More than 35 million nuclear medicine procedures are performed worldwide each year, more than half in the United States.

Covidien and the Institute of Atomic Energy in Poland announced the agreement yesterday. Adding the IAE POLATOM’S Maria Research Reactor to Covidien’s global supply chain, it is expected to help Covidien meet the needs of more than 1 million additional patients in just the first six months after the reactor begins supplying Mo 99.

“This is an historic agreement. It is the first time in decades that a new reactor has been brought into the global supply chain for medical isotopes,” said Timothy R. Wright, president, pharmaceuticals, Covidien. “We are excited that we will now be working together to provide more than a million patients around the globe with access to a critical medical isotope during this serious shortage.”

The announcement comes two days before the High Flux Reactor (HFR) in Petten, the Netherlands, is scheduled to begin a six-month shutdown for scheduled repairs. The remaining operating reactors supplying Covidien are the BR2 reactor in Belgium, the Osiris reactor in France and the Safari reactor in South Africa. Canada’s National Research Universal (NRU) reactor has been shut down for repairs since May 2009. When operating, the HFR and NRU reactors have typically provided approximately 65 percent of the world’s supply of medical isotopes.

The Maria Research Reactor, located approximately 30 km southeast of Warsaw, first operated from 1975 until 1985 when it was taken off line for a complete redesign. It resumed normal operations in 1993. Maria is considered to be a relatively new reactor, compared with the other five aging reactors that supply most of the world’s medical isotopes.

The announcement is the culmination of more than six months’ collaboration between Covidien and IAE POLATOM. Processing of Mo 99 produced during a test irradiation at the Maria Research Reactor last week is currently underway at Covidien's Petten facility. Tc 99m derived from the Mo 99 produced in Poland should be commercially available to help meet European needs within 30 days. Approval from the U.S. Food and Drug Administration is pending for use in the United States and from Health Canada for use in Canada.

“We are pleased to be cooperating with Covidien to use the scientific advancements we have made here at the Institute of Atomic Energy and the Maria Research Reactor to meet the healthcare needs of patients throughout the world at such a critical time,” said professor Krzysztof Wieteska, director of IAE POLATOM.

“This agreement with the IAE POLATOM will help us meet our short- and long-term needs for molybdenum 99,” said Wright. “We look forward to a productive relationship for the benefit of patients around the world.”

For more information: www.covidien.com

Related Content

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...